Bio-Tech this week: Liva, Volta Medical, Surgify Medical
Eleva Secures Up To €60M in Funding
Eleva, a Freiburg, Germany-based manufacturer of superior biologics, secured up to €60m in funding
Eleva leverages its moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. The company, which has developed drug candidates into clinical phases, intends to use the funds to advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies.
https://www.finsmes.com/2021/01/eleva-secures-up-to-e60m-in-funding.html
Berlin health tech startup Kenbi closes €7 million to boost the at-home nursing industry
Kenbi, a German startup that’s developing software to help nurses and fill gaps in the healthcare system, has raised €7 million in seed funding. The round was led by Redalpine, with existing investors Heartcore, e.ventures, and Partech on board as well. With a predicted shortage of up to 500,000 caregivers in the German system by 2030, the Berlin-based startup is on a mission to attract more people to the nursing profession by improving the job itself, re-centering patient care.
Berlin health tech startup Kenbi closes €7 million to boost the at-home nursing industry - Tech.eu
Kenbi, a German startup that’s developing…
CorWave Raises €35M in Funding
CorWave, a French medtech company developing an implantable heart pump, raised €35m in Series C
The company intends to use the new funds to complete the development of its wave membrane pump LVAD (Left Ventricular Assist Device), expand its manufacturing infrastructure as well as complete the regulatory testing required to conduct human implants and start clinical trials for advanced heart failure.
CorWave Raises €35M in Funding - FinSMEs
CorWave, a French medtech company developing an implantable heart pump, raised €35m in Series C financing
Liva Healthcare Secures €24.5M in Funding
Copenhagen, Denmark-based scalable digital health coaching company, raised €24.5m in funding. The round was led by Verlinvest. The company intends to use the funds to strengthen its position in Europe. Liva is a health tech company focused on digital health and lifestyle coaching for chronic disease prevention and management. The company plans to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change.
Liva Healthcare Secures €24.5M in Funding - FinSMEs
Liva Healthcare, a Copenhagen, Denmark-based scalable digital health coaching company, raised €24.5m in funding
French healthtech startup using AI to treat cardiac arrhythmias raises €23M
French healthtech startup Volta Medical works on novel artificial intelligence (AI) algorithms to treat cardiac arrhythmias. It has announced that has raised €23M funding led by Glide Healthcare along with participation from existing shareholder Pasteur Mutualité.
French healthtech startup using AI to treat cardiac arrhythmias raises €23M
French healthtech startup Volta Medical has raised €23M funding led by Glide Healthcare along with participation from existing shareholder Pasteur Mutualité.
Theolytics Raises $6.8M in Series A Funding
Theolytics, an Oxford, England-based biotech company harnessing viruses to combat cancer, closed a US $6.8m (UK £5m) Series A funding round. The round was co-led by Epidarex Capital and Taiho Ventures LLC with participation from existing investor, Oxford Sciences Innovation (OSI). The company intends to use the funds to progress its pipeline of candidates towards human clinical trials.
Theolytics Raises $6.8M in Series A Funding - FinSMEs
Theolytics, an Oxford, England-based biotech company harnessing viruses to combat cancer, closed a US $6.8m (UK £5m) Series A funding round
Turbine Raises €5.7M in Series A Funding
Turbine, a London, UK- and Budapest, Hungary-based company simulating cellular decision making to unlock novel oncology therapies, closed its €5.7m (USD 6.85m) pre-Series A funding round. The round was led by new investor Accel and included XTX Ventures and Boston Millenia Partners who joined the existing syndicate comprising Delin Ventures, Atlantic Labs and o2h Ventures.
Turbine Raises €5.7M in Series A Funding - FinSMEs
Turbine, a London, UK- and Budapest, Hungary-based company simulating cellular decision making to unlock novel oncology therapies, closed its €5.7m (USD 6.85m) pre-Series A funding round
Finland’s Surgify Medical wants to make bone surgeries safer with patented tech; raises €1.4M
Finnish healthtech company Surgify Medical aims to make bone surgery safer. It develops an internationally recognised surgical drill. In order to bring this surgical drill to the market, Surgify Medical has secured funding €1.4M funding from both domestic and foreign investors.
Finland’s Surgify Medical wants to make bone surgeries safer with patented tech; raises €1.4M
Finland’s healthtech startup Surgify Medical wants to make bone surgeries safer with patented tech; raises €1.4M funding.
This Lithuanian startup raises €500K to develop AI for generative protein design
Vilnius startup Biomatter Designs claims to pioneer the technologies for generative protein design. The company will be able to generate novel enzymes and protein therapeutics that would otherwise be tedious to obtain by classical experimental and computational approaches. Biomatter Designs just announced that it raised €500k led by Practica Capital along with 70V and angel investors. This fund will be used to develop the company’s protein design technology and product pipeline further.
This Lithuanian startup raises €500K to develop AI for generative protein design
This Lithuanian startup, Biomatter Designs raises €500K to develop AI for generative protein design.
Hinge Health raises $300M at $3B valuation as #1 Digital Clinic for back and joint pain; revenue quadrupled year over year
Hinge Health is announcing a $300M Series D round to expand clinical capabilities as an end-to-end Digital MSK Clinic for all back and joint pain care. The fundraising was heavily oversubscribed and jointly led by Coatue Management and Tiger Global with participation from existing investors Atomico, Insight Partners, Quadrille, 11.2 Capital, Lead Edge Capital, Bessemer Venture Partners, and Heuristic Capital.
Hinge Health raises $300M at $3B valuation as #1 Digital Clinic for back and joint pain; revenue quadrupled year over year
SAN FRANCISCO (PRWEB) January 07, 2021 -- Fundraising jointly led by Coatue Management and Tiger Global raises valuation of Hinge Health to $3B, one of the highest valuations for a private digital health company. A landmark year for Hinge Health: in 2020, the customer base tripled, revenue quadrupled, and customer retention held at 100%.
Affinivax Raises $226M in Series C Financing
Affinivax, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, closed a $226m Series C financing. The round was co-led by new investors Rock Springs Capital and Foresite Capital.
The company intends to use the funds to continue advancing its MAPS vaccine pipeline for a range of infectious diseases, including its lead pneumococcal vaccine candidates and vaccine candidates targeting healthcare-associated infections where previous vaccine approaches have not been successful.
Affinivax Raises $226M in Series C Financing - FinSMEs
Affinivax, Inc., a Cambridge, MA-based clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, closed a $226m Series C financing
Atalanta Therapeutics Raises $110M in Series A Funding
Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding. The financing was provided exclusively by F-Prime Capital. Additionally, Atalanta announced strategic collaborations with Biogen (Nasdaq: BIIB) and Genentech, a member of the Roche Group.
Atalanta Therapeutics Raises $110M in Series A Funding - FinSMEs
Atalanta Therapeutics, a Boston, MA-based biotechnology company pioneering new treatment options for neurodegenerative diseases, raised $110m in Series A funding
Senti Bio raises $105 million for its new programmable biology platform and cancer therapies
Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, said it has raised $105 million in a new round of financing led by the venture arm of life sciences giant Bayer. The company’s technology uses new computational biological techniques to manufacture cell and gene therapies that can more precisely target specific cells in the body. https://techcrunch.com/2021/01/06/senti-bio-raises-105-million-for-its-new-programmable-biology-platform-and-cancer-therapies/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29&guccounter=1
DiCE Molecules Raises $80M in Series C Financing
DiCE Molecules, a South San Francisco, Calif.-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, completed an $80m Series C financing. The round was led by RA Capital Management with participation from some new investors. Led by Kevin Judice, Ph.D., Chief Executive Officer, DiCE is a biotechnology company utilizing its proprietary DNA-encoded library (DEL) technology, combined with unique structural insights, to generate small molecule antagonists against a range of protein-protein-interface (PPI) targets.
DiCE Molecules Raises $80M in Series C Financing - FinSMEs
DiCE Molecules, a South San Francisco, Calif.-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology, completed an $80m Series C financing
Endeavor BioMedicines raises $62 million to combat pulmonary disease
A new startup has officially emerged from stealth with the raise of its $62 million Series A funding round. Endeavor BioMedicines is led by co-founder and CEO John Hood, who previously led Impact Biomedicines, and its new funding comes from Omega Funds and Longitude Capital, as well as the company’s own management team. Endeavor’s goal is to develop treatments specifically to address pulmonary disease, and the startup is putting its funding toward two phase 2 clinical trials that will seek to determine whether their therapeutic candidate can reverse or slow the progression of idiopathic pulmonary fibrosis (IPF), a very common type of pulmonary fibrosis that results in long tissue scarring that causes difficulty in breathing for affected patients. https://techcrunch.com/2021/01/07/endeavor-biomedicines-raises-62-million-to-combat-pulmonary-dissease/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29
Myeloid Therapeutics Raises Over $50M in Financing
Myeloid Therapeutics, Inc., a Cambridge, Mass.-based company harnessing and reprogramming myeloid cells for treating cancers, launched with over $50m in financing. The round was led by Newpath Partners with participation from 8VC, Hatteras Venture Partners and Alexandria Venture Investments. Myeloid Therapeutics is an immunology company focused on combining biology insights with technologies to harness myeloid cells and eradicate cancer and other diseases. https://www.finsmes.com/2021/01/myeloid-therapeutics-raises-over-50m-in-financing.html
Carrum Health Raises $40M in Series A Funding
Carrum Health, a San Francisco, CA-based digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform, closed a $40m Series A funding. The round was led by Tiger Global Management LLC, with participation from GreatPoint Ventures and Cross Creek and return investors Wildcat Venture Partners and SpringRock Ventures. The company intends to use the funds to expand its offerings to more employers, provide access to additional healthcare services and enhance technology to support its roster of clients and providers.
Carrum Health Raises $40M in Series A Funding - FinSMEs
Carrum Health, a San Francisco, CA-based digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform, closed a $40m Series A funding
Neuros Medical Raises $38.5M in Series BB Funding
Neuros Medical, Inc., a Willoughby Hills, OH-based medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, closed a Series BB financing totaling $38.5m. The company intends to use the funds to complete enrollment of the pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study, and to submit an anticipated application for Pre-Market Approval.
Neuros Medical Raises $38.5M in Series BB Funding - FinSMEs
Neuros Medical, Inc., a Willoughby Hills, OH-based medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, closed a Series BB financing totaling $38.5m
Mana Therapeutics Raises $35M Series A Financing
Mana Therapeutics, a Waltham, Mass.-based clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, raised $35m in Series A financing. The round was was led by Cobro Ventures and Lightchain Capital, with participation from LifeSci Venture Partners and other undisclosed investors. Mana is using its EDIFY™ platform to develop a pipeline of proprietary and partnered off-the-shelf cell therapies for cancer patients across a broad range of liquid and solid tumors, with an initial focus on relapsed acute myeloid leukemia (AML).
Mana Therapeutics Raises $35M Series A Financing
Mana Therapeutics, a Waltham, Mass.-based clinical-stage company creating nonengineered, off-the-shelf allogeneic cell therapies that target multiple cancer antigens, raised $35m in Series A financing
SpyGlass Ophthalmics Closes $27.5M in Series B Financing
SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing. The round was led by Vensana Capital with participation from existing investor New Enterprise Associates. The company intends to use the funds to further advance development efforts of platform technology.
SpyGlass Ophthalmics Closes $27.5M in Series B Financing - FinSMEs
SpyGlass Ophthalmics, a Mission Viejo, CA-based ophthalmic therapeutics company, secured $27.5m in Series B financing
Monument Raises $10.3M in Series A Funding
Monument Inc., a NYC-based brand in consumerized healthcare for alcohol use disorder, closed a $10.3m (USD) Series A funding. The round, which brings its total capital raised to $17.8m, was led by VMG Catalyst. The company intends to use the funds to expand product initiatives. https://www.finsmes.com/2021/01/monument-raises-10-3m-in-series-a-funding.html
Emboline Raises Over $10M in Series C Funding
Emboline, Inc., a Santa Cruz, CA-based medical technology company focused on reducing stroke during transcatheter heart procedures, completed an over $10m in Series C funding. Backers included new and existing investors. The company intends to use the funds to obtain initial commercial approval of the Emboliner and to launch its upcoming US IDE clinical study, which are both anticipated in 2021. https://www.finsmes.com/2021/01/emboline-raises-over-10m-in-series-c-funding.html
Vision Fund backs Chinese fitness app Keep in $360 million round
Keep said it has recently closed a Series F financing round of $360 million led by SoftBank Vision Fund. Keep started out in 2014 by providing at-home workout videos and signed up 100 million users within three years. As of late, it has served over 300 million users, the company claims. It has over time fostered an ecosystem of fitness influencers who give live classes to students via videos and now runs a team of course designers, streaming coaches and operational staff dedicated to its video-streaming business. https://techcrunch.com/2021/01/10/vision-fund-keep-360-million-funding/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29
Visen Pharmaceuticals Closes $150M Series B Financing
Visen Pharmaceuticals, a Shangai, China-based biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, closed a $150m Series B financing. The round was led by Sequoia China with participation from others. The company intends to use the funds to accelerate the clinical development of drug candidates and to build commercialization foundation.
Visen Pharmaceuticals Closes $150M Series B Financing - FinSMEs
Visen Pharmaceuticals, a Shangai, China-based biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, closed a $150m Series B financing
NuProbe Raises $42M in Funding
NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round. The round was led by BioTrack Capital and Yonghua Capital with participation from others. The company intends to use the funds to expand the commercial team in both the US and China, develop new NGS products, and file for regulatory approval in China for NuProbe’s clinical products.
NuProbe Raises $42M in Funding - FinSMEs
NuProbe, a Houston, USA, Shanghai, China and Suzhou, China-based genomics and molecular diagnostics company specialized in ultrasensitive sequencing panels, closed a $42M funding round
Cairo-based telemedicine startup secures six-figure funding
Docspert Health has secured a six-figure undisclosed amount of funding. The funding will reportedly be used to expand the startup’s current services across Egypt and the Arabian Gulf. Launched in February 2020, Docspert Health is the first telemedicine platform that connects patients in the Middle East and Africa with leading international medical experts.
Cairo-based telemedicine startup secures six-figure funding - Ventureburn
Egypt-based telemedicine startup, Docspert Health has secured a six-figure seed funding investment from Flat6Labs and angel investors from the US and UK.
Sanofi buys British Biotech-company for more than 1 billion dollars
The French pharmaceutical company Sanofi buys the British bio-tech company Kymab for $1.1 billion. With this buy, Sanofi secures its rights for a promising antibody that fights against autoimmune diseases and infectious diseases.
https://www.faz.net/aktuell/rhein-main/thema/sanofiCORE Industrial Partners Portfolio Company Incodema Acquires Mark Two Engineering
CORE, a Chicago-based private equity firm, announced today the acquisition of Mark Two Engineering, LLC, a medical device contract manufacturing provider, by CORE portfolio company Incodema Holdings LLC. Founded in 1996 and headquartered in Miami Lakes, Florida, Mark Two specializes in complex high-precision machining and manufacturing for established medical device OEMs. The Company provides components, surgical equipment, and implant systems across multiple product platforms through a full suite of modern CNC technologies and equipment, including swiss screw machines, lathes, multi-axis mills and grinders. Mark Two is ISO 9001 certified, ISO 13485 certified and FDA registered.
